menu search

HQL / Equity CEFs: What's Going On With Tekla's HQH And HQL?

Equity CEFs: What's Going On With Tekla's HQH And HQL?
The iShares Biotechnology ETF (IBB) is down -12.9% year-to-date but the Tekla biotech equity CEFs are down even more despite NAVs that are holding up extremely well. The result is that the Tekla biotech CEFs (HQH) and (HQL) keep dropping to lower-and-lower valuations with HQH now at a -11.6% discount and HQL at a -12.0% discount. Read More
Posted: Dec 8 2022, 10:36
Author Name: Seeking Alpha
Views: 101975

HQL News  

HQL: Hold Your Investments In This Healthcare CEF For Strong, Steady Yield

By Seeking Alpha
September 27, 2023

HQL: Hold Your Investments In This Healthcare CEF For Strong, Steady Yield

Tekla Life Sciences Investors invests primarily in biotechnology stocks, and 10-12 large-cap biotech stocks (50% of total holdings) sets the trend and more_horizontal

HQL: 13% Discount Creates An Opportunity

By Seeking Alpha
June 29, 2023

HQL: 13% Discount Creates An Opportunity

HQL: 13% Discount Creates An Opportunity more_horizontal

HQL: Boom-Bust Returns May Not Be Suitable For High Distribution Yield

By Seeking Alpha
March 8, 2023

HQL: Boom-Bust Returns May Not Be Suitable For High Distribution Yield

HQL focuses on the life sciences industry with a 74% allocation to biotechnology stocks. It pays a 2% quarterly managed distribution. more_horizontal

Equity CEFs: What's Going On With Tekla's HQH And HQL?

By Seeking Alpha
December 8, 2022

Equity CEFs: What's Going On With Tekla's HQH And HQL?

The iShares Biotechnology ETF (IBB) is down -12.9% year-to-date but the Tekla biotech equity CEFs are down even more despite NAVs that are holding up more_horizontal

HQL: Buy For The Yield, If You Can Stomach The Depreciation

By Seeking Alpha
April 27, 2022

HQL: Buy For The Yield, If You Can Stomach The Depreciation

HQL pays regular quarterly dividends with a close to double-digit yield, and despite poor price growth over medium and long run, HQL's total return is more_horizontal

Tekla Life Sciences Investors: Buy For Steady, Quarterly Dividend

By Seeking Alpha
February 11, 2022

Tekla Life Sciences Investors: Buy For Steady, Quarterly Dividend

HQL pays quarterly dividends. Even during the pandemic, its performance has been better than its peers. Current prices look attractive. more_horizontal

Tekla Life Sciences Investors: Buy For Steady, Quarterly Dividend

By Seeking Alpha
February 11, 2022

Tekla Life Sciences Investors: Buy For Steady, Quarterly Dividend

HQL pays quarterly dividends. Even during the pandemic, its performance has been better than its peers. Current prices look attractive. more_horizontal

Tekla Life Sciences Investors: Buy For Steady, Quarterly Dividend

By Seeking Alpha
February 11, 2022

Tekla Life Sciences Investors: Buy For Steady, Quarterly Dividend

HQL pays quarterly dividends. Even during the pandemic, its performance has been better than its peers. Current prices look attractive. more_horizontal


Search within

Pages Search Results: